Works Cited

1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018. Available at https://www.cdc.gov/std/stats18/default.htm. Last accessed March 18, 2020.

2. Centers for Disease Control and Prevention. Incidence, Prevalence, and Cost of Sexually Transmitted Infections in the United States. Available at https://npin.cdc.gov/publication/incidence-prevalence-and-cost-sexually-transmitted-infections-united-states. Last accessed March 18, 2020.

3. Centers for Disease Control and Prevention. New CDC Report: STDs Continue to Rise in the U.S. Available at https://www.cdc.gov/nchhstp/newsroom/2019/2018-std-surveillance-report-press-release.html. Last accessed March 18, 2020.

4. Walensky RP, Houry D, Jernigan DB, Bunnell R, Layden J, Iademarco MF. Sexually transmitted infections treatment guidelines, 2021. MMWR. 2021;70(4):1

5. Centers for Disease Control and Prevention. Summary of Notifiable Diseases, United States, 1995. Available at https://www.cdc.gov/mmwr/preview/mmwrhtml/00044418.htm. Last accessed March 18, 2020.

6. Centers for Disease Control and Prevention. 2020 National Notifiable Conditions. Available at https://wwwn.cdc.gov/nndss/conditions/notifiable/2020/. Last accessed March 18, 2020.

7. U.S. Preventive Services Task Force. Final Recommendation Statement: Sexually Transmitted Infections: Behavioral Counseling. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/sexually-transmitted-infections-behavioral-counseling1. Last accessed March 18, 2020.

8. Crosby RA, Charnigo RA, Weathers C, Caliendo AM, Shrier LA. Condom effectiveness against non-viral sexually transmitted infections: a prospective study using electronic daily diaries. Sex Transm Infect. 2012;88(7):484-489.

9. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82(6):454-461.

10. Warner L, Stone KM, Macaluso M, Buehler JW, Austin HD. Condom use and risk of gonorrhea and chlamydia: a systematic review of design and measurement factors assessed in epidemiologic studies. Sex Transm Dis. 2006;33(1):36-51.

11. Ness RB, Randall H, Richter HE, et al. Condom use and the risk of recurrent pelvic inflammatory disease, chronic pelvic pain, or infertility following an episode of pelvic inflammatory disease. Am J Public Health. 2004;94(8):1327-1329.

12. Hernández-Romieu AC, Siegler AJ, Sullivan PS, Crosby R, Rosenberg ES. How often do condoms fail? A cross-sectional study exploring incomplete use of condoms, condom failures, and other condom problems among black and white MSM in southern USA. Sex Transm Infect. 2014;90(8):602-627.

13. D'Anna LH, Margolis AD, Warner L, et al. Condom use problems during anal sex among men who have sex with men (MSM): findings from the safe in the city study. AIDS Care. 2012;24(8):1028-1038.

14. Steiner MJ, Cates W Jr, Warner L. The real problem with male condoms is nonuse. Sex Transm Dis. 1999;26(8):459-462.

15. Hatcher RA. Contraceptive Technology. 21st ed. Atlanta, GA: Managing Contraception LLC; 2018.

16. Minuk GY, Bohme CE, Bowen TJ, et al. Efficacy of commercial condoms in the prevention of hepatitis B virus infection. Gastroenterology. 1987;93(4):710-714.

17. Martin ET, Krantz E, Gottlieb SL, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med. 2009;169(13):1233-1240.

18. Gallo MF, Kilbourne-Brook M, Coffey PS. A review of the effectiveness and acceptability of the female condom for dual protection. Sex Health. 2012;9(1):18-26.

19. Mantell JE, Kelvin EA, Exner TM, Hoffman S, Needham S, Stein ZA. Anal use of the female condom: does uncertainty justify provider inaction? AIDS Care. 2009;21(9):1185-1194.

20. Rosenberg MJ, Davidson AJ, Chen JH, Judson FN, Douglas JM. Barrier contraceptives and sexually transmitted diseases in women: a comparison of female-dependent methods and condoms. Am J Public Health. 1992;82(5):669-674.

21. de Bruyn G, Shiboski S, van der Straten A, et al. The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. Sex Transm Infect. 2011;87(4):301-305.

22. Ramjee G, van der Straten A, Chipato T, et al. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One. 2008;3(10):e3488.

23. Myer L, Kuhn L, Stein ZA, Wright TC Jr, Denny L. Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis. 2005;5(12):786-794.

24. Centers for Disease Control and Prevention. Sexually Transmitted Infection Treatment Guidelines, 2021: Provider Resources. Available at https://www.cdc.gov/std/treatment-guidelines/provider-resources.htm. Last accessed October 14, 2021.

25. Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines, 2021: Screening Recommendations and Considerations Referenced in Treatment Guidelines and Original Sources. Available at https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm. Last accessed October 13, 2021.

26. U.S. Preventive Services Task Force. Screening for chlamydia and gonorrhea U.S. Preventive Services Task Force recommendation statement. JAMA. 2021;326(10):949-956.

27. Papp JR, Schachter J, Gaydos CA, Van Der Pol B. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae—2014. MMWR. 2014;63(RR2):1-19.

28. Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance—the Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. MMWR. 2016;65(7):1-19

29. Taylor SN, DiCarlo RP, Martin DH. Comparison of methylene blue/gentian violet stain to Gram's stain for the rapid diagnosis of gonococcal urethritis in men. Sex Transm Dis. 2011;38(11):995-996.

30. American Association for Clinical Chemistry. Syphilis Tests. Available at https://labtestsonline.org/tests/syphilis-tests. Last accessed March 18, 2020.

31. Hogben M, Collins D, Hoots B, O'Connor K. Partner services in STD prevention programs: a review. Sex Transm Dis. 2016;43(001):S53-S62.

32. Centers for Disease Control and Prevention. Expedited Partner Therapy. Available at https://www.cdc.gov/std/ept/default.htm. Last accessed March 18, 2020.

33. Microbiologics. Neisseria gonorrhoeae: Combating a Multidrug-Resistant Organism. Available at https://blog.microbiologics.com/neisseria-gonorrhoeae-combating-a-multidrug-resistant-organism/. Last accessed March 18, 2020.

34. Committee on Gynecologic Practice. ACOG committee opinion no. 645: dual therapy for gonococcal infections. Obstet Gynecol. 2015;126(5):e95-e99.

35. Barrow RY, Ahmed F, Bolan GA, Workowski KA. Recommendations for providing quality sexually transmitted diseases clinical services, 2020. MMWR. 2020;68(RR5):1-20.

36. Nwokolo NC, Dragovic B, Patel S, Tong CY, Barker G, Radcliffe K. 2015 UK national guideline for the management of infection with Chlamydia trachomatis. Int J STD AIDS. 2016;27(4):251-267.

37. Morré SA, van den Brule AJ, Rozendaal L, et al. The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS. 2002;13(2):12-18.

38. Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW III. The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment. Sex Transm Dis. 2008;35(2):119-123.

39. American Association for Clinical Chemistry. Chlamydia Testing. Available at https://labtestsonline.org/tests/chlamydia-testing. Last accessed March 18, 2020.

40. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. 2002;29(9):497-502.

41. Hathorn E, Opie C, Goold P. What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women? Sex Transm Infect. 2012;88(5):352-354.

42. Steedman NM, McMillan A. Treatment of asymptomatic rectal Chlamydia trachomatis: is single-dose azithromycin effective? Int J STD AIDS. 2009;20(1):16-18.

43. Bernstein KT, Stephens SC, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis. 2009;49(12):1793-1797.

44. Marcus JL, Kohn RP, Barry PM, Philip SS, Bernstein KT. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the female oropharynx to the male urethra. Sex Transm Dis. 2011;38(5):372-373.

45. Renault CA, Israelski DM, Levy V, Fujikawa BK, Kellogg TA, Klausner JD. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health. 2011;8(1):69-73.

46. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation. 11th ed. Philadelphia, PA: Wolters Kluwer; 2017.

47. Kacmar J, Cheh E, Montagno A, Peipert JF. A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy. Infect Dis Obstet Gynecol. 2001;9(4):197-202.

48. Rahangdale L, Guerry S, Bauer HM, et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex Transm Dis. 2006;33(2):106-110.

49. LeFevre ML, U.S. Preventative Services Task Force. Screening for chlamydia and gonorrhea: U.S. Preventative Services Task Force recommendation statement. Ann Intern Med. 2014;161(12):902-910.

50. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis. 2010;201(Suppl 2):S88-S95.

51. National Institute of Allergy and Infectious Diseases. Diseases and Conditions. Available at https://www.niaid.nih.gov/diseases-conditions/infectious-diseases. Last accessed March 18, 2020.

52. Eunice Kennedy Shriver National Institute of Child Health and Human Development. What Are Some Types of and Treatments for Sexually Transmitted Diseases (STDs) or Sexually Transmitted Infections (STIs)? Available at https://www.nichd.nih.gov/health/topics/stds/conditioninfo/types. Last accessed March 18, 2020.

53. Fairley CK, Hocking JS, Zhang L, Chow EP. Frequent transmission of gonorrhea in men who have sex with men. Emerg Infect Dis. 2017;23(1):102-104.

54. American Association for Clinical Chemistry. Gonorrhea Testing. Available at https://labtestsonline.org/tests/gonorrhea-testing. Last accessed March 18, 2020.

55. Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydia and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis. 2008;35(7):637-642.

56. Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol. 2010;48(5):1827-1832.

57. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR. 2012;61(31):590-594.

58. Centers for Disease Control and Prevention. CDC Fact Sheet: Addressing the Threat of Drug-Resistant Gonorrhea. Available at https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/drug-resistant-gonorrhea.pdf. Last accessed March 19, 2020.

59. Lyss SB, Kamb ML, Peterman TA, et al. Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann Intern Med. 2003;139(3):178-185.

60. Barbee LA, Kerani RP, Dombrowski JC, Soge OO, Golden MR. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis. 2013;56(11):1539-1545.

61. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis. 1995;20 (Suppl 1):S47-S65.

62. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis. 2007;44(Suppl 3):S84-S101.

63. St. Cyr S, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. MMWR. 2020;69(50):1911-1916.

64. Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg. 2007;136(3):340-347.

65. Ahmed KA, Fox SJ, Frigas E, Park MA. Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy. Int Arch Allergy Immunol. 2012;158(4):405-410.

66. Romano A, Gaeta F, Valluzzi RL, Caruso C, Rumi G, Bousquet PJ. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol. 2010;126(5):994-999.

67. National Network of STD Clinical Prevention Training Centers. Available at https://nnptc.org. Last accessed March 19, 2020.

68. Belkacem A, Caumes E, Ouanich J, et al. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009–2011. Sex Transm Infect. 2013;89(8):613-615.

69. Kingston M, French P, Higgins S, et al. UK national guidelines on the management of syphilis 2015. Int J STD AIDS. 2016;27(6):421-446.

70. Public Health Agency of Canada. Section 5-10: Canadian Guidelines on Sexually Transmitted Infections. Management and Treatment of Specific Infections: Syphilis. Available at https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections/canadian-guidelines-sexually-transmitted-infections-27.html. Last accessed March 19, 2020.

71. Mullooly C, Higgins SP. Secondary syphilis: the classical triad of skin rash, mucosal ulceration and lymphadenopathy. Int J STD AIDS. 2010;21(8):537-545.

72. Association of Public Health Laboratories. Overview of Syphilis Diagnostics: Serologic Assays and Algorithms. Available at https://www.aphl.org/programs/infectious_disease/std/Pages/Syphilis.aspx. Last accessed March 18, 2020.

73. Mayo Clinic Laboratories. Syphilis IgG Antibody with Reflex, Serum. Available at https://www.mayocliniclabs.com/test-notifications/attachment.php?id=57987. Last accessed Marczh 19, 2020.

74. Association of Public Health Laboratories. Suggested Reporting Language for Syphilis Serology Testing. Available at https://www.aphl.org/aboutAPHL/publications/Documents/ID_Suggested_Syphilis_Reporting_Lang_122015.pdf. Last accessed March 19, 2020.

75. Sparling PF. Diagnosis of neurosyphilis: new tools. Sex Transm Dis. 2010;37(5):288-289.

76. Krüger C, Malleyeck I. Congenital syphilis: still a serious, under-diagnosed threat for children in resource-poor countries. World J Pediatr. 2010;6(2):125-131.

77. Frentz G, Nielsen PB, Espersen F, Czartoryski A, Aastrup H. Penicillin concentrations in blood and spinal fluid after a single intramuscular injection of penicillin G benzathine. Eur J Clin Microbiol. 1984;3(2):147-149.

78. Collart P, Poitevin M, Milovanovic A, Herlin A, Durel J. Kinetic study of serum penicillin concentrations after single doses of benzathine and benethamine penicillins in young and old people. Br J Vener Dis. 1980;56(6):355-362.

79. Hagdrup HK, Lange Wantzin G, Secher L, Rosdahl VT. Penicillin concentrations in serum following weekly injections of benzathine penicillin G. Chemotherapy. 1986;32(2):99-101.

80. Centers for Disease Control and Prevention. Inadvertent use of Bicillin C-R to treat syphilis infection—Los Angeles, California, 1999–2004. MMWR. 2005;54(09):217-219.

81. Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced for early syphilis in patients with and without human immunodeficiency virus infection. The syphilis and HIV study group. N Engl J Med. 1997;337(5):307-314.

82. Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis. 2004;38(7):1001-1006.

83. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Neurosyphilis ina clinical cohort of HIV-1-infected patients. AIDS. 2008;22(10):1145-1151.

84. Marra CM, Maxwell CL, Tantalo LC, Sahi SK, Lukehart SA. Normalization of serum rapid plasma regain titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis. 2008;47(7):893-899.

85. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis. 2008;47(2):258-265.

86. Seña AC, Wolff M, Martin DH, et al. Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis. Clin Infect Dis. 2011;53(11):1092-1099.

87. Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics. Sex Transm Infect. 2007;83(2):97-101.

88. Seña AC, Wolff M, Behets F, et al. Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin. Clin Infect Dis. 2013;56(3):420-422.

89. Nathanl L, Bawdon RE, Sidawi JE, Stettler RW, McIntire DM, Wendel GD Jr. Penicillin levels following the administration of benzathine penicillin G in pregnancy. Obstet Gynecol. 1993;82(3):338-342.

90. The Conference Exchange. Comparative Effectiveness of 1 Dose Versus 3 Doses of Benzathine Penicillin in the Treatment of Early Syphilis in HIV-Infected Patients: A Multicenter, Prospective Observational Study in Taiwan. Available at https://idsa.confex.com/idsa/2013/webprogram/Paper40099.html. Last accessed March 19, 2020.

91. Leeyaphan C, Ong JJ, Chow EP, et al. Systematic review and meta-analysis of doxycycline efficacy for rectal lymphogranuloma venereum in men who have sex with men. Emerg Infect Dis. 2016;22(10):1778-1784.

92. Ward H, Martin I, Macdonald N, et al. Lymphogranuloma venereum in the United Kingdom. Clin Infect Dis. 2007;44(1):26-32.

93. Pallawela SN, Sullivan AK, Macdonald N, et al. Clinical predictors of rectal lymphogranuloma venereum infection: results from a multicenter case-control study in the U.K. Sex Transm Infect. 2014;90(4):269-274.

94. de Vrieze NH, de Vries HJ. Lymphogranuloma venereum among men who have sex with men: an epidemiological and clinical review. Expert Rev Anti Infect Ther. 2014;12(6):697-704.

95. White JA. Manifestations and management of lymphogranuloma venereum. Curr Opin Infect Dis. 2009;22(1):57-66.

96. White J, O'Farrell N, Daniels D. 2013 UK national guideline for the management of lymphogranuloma venereum: clinical effectiveness group of the British Association for Sexual Health and HIV (CEG/BASHH) Guideline development group.Sage Journals. 2013;24(8):593-601.

97. Haar K, Dudareva-Vizule S, Wisplinghoff H, et al. Lymphogranuloma venereum in men screened for pharyngeal and rectal infection, Germany. Emerg Infect Dis. 2013;19(3):488-492.

98. Martin-Iguacel R, Llibre JM, Nielsen H, et al. Lymphogranuloma venereum proctocolitis: a silent endemic disease in men who have sex with men in industrialized countries. Eur J Clin Microbiol Infect Dis. 2010;29(8):917-925.

99. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353(18):1899-1911.

100. Swidsinski A, Mendling W, Loening-Baucke V. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106(5 Pt 1):1013-1023.

101. American Association for Clinical Chemistry. Vaginitis and Vaginosis. Available at https://labtestsonline.org/conditions/vaginitis-and-vaginosis. Last accessed March 19, 2020.

102. British Association for Sexual Health and HIV. UK National Guideline for the Management of Bacterial Vaginosis. Available at https://www.guidelinecentral.com/summaries/uk-national-guideline-for-the-management-of-bacterial-vaginosis-2012/#section-society. Last accessed March 19, 2020.

103. Brotman RM, Klebanoff MA, Nansel TR, et al. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis. 2010;202(12):1907-1915.

104. Cherpes TL, Wiesenfeld HC, Melan MA, et al. The associations between pelvic inflammatory disease, trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis. 2006;33(12):747-752.

105. Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacterial vaginosis outcomes in women. Sex Transm Dis. 2012;39(10):822-830.

106. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22.

107. Ison CA, Hay PE. Validation of a simplified grading of gram stained vaginal smears for use in genitourinary medicine clinics.Sex Transm Infect. 2002;78(6):413-415.

108. Lugo-Miro VI, Green M, Mazur L. Comparison of different metronidazole therapeutic regimens for bacterial vaginosis: a meta-analysis. JAMA. 1992;268(1):92-95.

109. Greaves WL, Chungafung J, Morris B, Haile A, Townsend JL. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. Obstet Gynecol. 1988;72(5):799-802.

110. Schwebke JR, Desmond RA. Tinidazole versus metronidazole for the treatment of bacterial vaginosis. Am J Obstet Gynecol. 2011;204(3):e1-e211.

111. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 194(5):1283-1289.

112. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis.Sex Transm Dis. 2009;36(11):732-734.

113. McClelland RS, Richardson BA, Hassan WM, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis. 2008;197(10):1361-1368.

114. Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol. 2001;98(4):656-663.

115. Lamont RF, Nhan-Chang CL, Sobel JD, Workowski K, Conde-Agudelo A, Romero R. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and meta-analysis.Am J Obstet Gynecol. 2011;205(3):177-190.

116. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013;(1):CD000262.

117. Government of Canada. Section 4-2: Canadian Guidelines on Sexually Transmitted Infections. Management and Treatment of Specific Syndromes: Epididymitis. Available at https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections/canadian-guidelines-sexually-transmitted-infections-20.html. Last accessed March 19, 2020.

118. Trojian TH, Lishnak TS, Heiman D. Epididymitis and orchitis: an overview. Am Fam Physician. 2009;79(7):583-587.

119. Tracy CR, Costabile RA. The evaluation and treatment of acute epididymitis in a large university-based population: are CDC guidelines being followed? World J Urol. 2009;27(2):259-263.

120. Tracy CR, Steers WD, Costabile R. Diagnosis and management of epididymitis. Urol Clin North Am. 2008;35(1):101-108.

121. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005;352(7):676-685.

122. Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis. 2003;30(1):49-56.

123. Kemp M, Christensen JJ, Lautenschlager S, Vall-Mayans M, Moi H. European guideline for the management of chancroid, 2011.Int J STD AIDS. 2011;22(5):241-244.

124. Government of Canada. Section 5-1: Canadian Guidelines on Sexually Transmitted Infections. Management and Treatment of Specific Infections: Chancroid. Available at https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections/canadian-guidelines-sexually-transmitted-infections-29.html. Last accessed March 19, 2020.

125. Lewis DA. Chancroid: clinical manifestations, diagnosis, and management. Sex Transm Infect. 2003;79(1):68-71.

126. Malonza IM, Tyndall MW, Ndinya-Achola JO, et al. A randomized, double-blind, placebo-controlled trial of single-dose ciprofloxacin versus erythromycin for the treatment of chancroid in Nairobi, Kenya. J Infect Dis. 1999;180(6):1886-1893.

127. Tyndall MW, Agoki E, Plummer FA, Malisa W, Ndinya-Achola JO, Ronald AR. Single dose azithromycin for the treatment of chancroid: a randomized comparison with erythromycin. Sex Transm Dis. 1994;21(4):231-234.

128. Velho PE, Souza EM, Belda Junior W. Donovanosis. Braz J Infect Dis. 2008;12(6):521-525.

129. O'Farrell N. Donovanosis. Sex Transm Infect. 2002;78(6):452-457.

130. Bowden F. Donovanosis in Australia: going, going…. Sex Transm Infect. 2005;81(5):365-366.

131. Lau A, Bradshaw CS, Lewis D, et al. The efficacy of azithromycin for the treatment of genital Mycoplasma genitalium: a systematic review and meta-analysis. Clin Infect Dis. 2015;61(9):1389-1399.

132. Daley GM, Russell DB, Tabrizi SN, McBride J. Mycoplasma genitalium: a review. Int J STD AIDS. 2014;25(7):475-487.

133. Ona S, Molina RL, Diouf K. Mycoplasma genitalium: an overlooked sexually transmitted pathogen in women? Infect Dis Obstet Gynecol. 2016;2016:4513089.

134. Centers for Disease Control and Prevention. Mycoplasma genitalium. Available at https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm. Last accessed October 14, 2021.

135. U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA Updates Warnings for Oral and Injectable Fluoroquinolone Antibiotics Due to Disabling Side Effects. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics. Last accessed March 19, 2020.

136. Macy E, Poon K-Y T. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009;122(8):778.

137. Lee CE, Zembower TR, Fotis MA, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med. 2000;160(18):2819-2822.

138. del Real GA, Rose ME, Ramirez-Atamoros MT, et al. Penicillin G skin testing in patients with a history of beta-lactam allergy.Ann Allergy Asthma Immunol. 2007;98(4):355-359.

139. Wong BB, Keith PK, Waserman S. Clinical history as a predictor of penicillin skin test outcome. Ann Allergy Asthma Immunol. 2006;97(2):169-174.

140. Park MA, Koch CA, Klemawesch P, Joshi A, Li JT. Increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol. 2010;153(3):268-273.

141. Sogn DD, Evans R III, Shepherd GM, et al. Results of the national institute of allergy and infectious diseases collaborative clinical trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med. 1992;152(5):1025-1032.

142. Macy E, Ngor EW. Safely diagnosing clinically significant penicillin allergy using only penicilloyl-poly-lysine, penicillin, and oral amoxicillin. J Allergy Clin Immunol Pract. 2013;1(3):258-263.

143. Albin S, Agarwal S. Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population. Allergy Asthma Proc. 2014;35(6):489-494.

144. Legere HJ III, Palis RI, Rodriguez Bouza T, Uluer AZ, Castells MC. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros. 2009;8(6):418-424.

145. Borish L, Tamir R, Rosenwasser LJ. Intravenous desensitization to beta-lactam antibiotics. J Allergy Clin Immunol. 1987;80(3 Pt 1):314-319.

146. Bodie M, Gale-Rowe M, Alexandre S, Auguste U, Tomas K, Martin I. Addressing the rising rates of gonorrhea and drug-resistant gonorrhea: there is no time like the present. Can Commun Dis Rep. 2019;45(2-3):54–62.

147. U.S. Food and Drug Administration. FDA Allows for First Point-of-Care Chlamydia and Gonorrhea Test to be Used in More Near-Patient Care Settings. Available at https://www.fda.gov/news-events/press-announcements/fda-allows-first-point-care-chlamydia-and-gonorrhea-test-be-used-more-near-patient-care-settings. Last accessed October 11, 2021.

Evidence-Based Practice Recommendations Citations

1. U.S. Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. JAMA. 2021;326(10):949-956. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening. Last accessed October 14, 2021.

2. Minnesota Department of Health. Syphilis Treatment Protocol: Clinical Guidance for Primary, Secondary, and Latent Syphilis. Available at https://www.health.state.mn.us/diseases/syphilis/hcp/protocol.pdf. Last accessed April 23, 2020.

3. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2021: Bacterial Vaginosis. Available at https://www.cdc.gov/std/treatment-guidelines/bv.htm. Last accessed October 14, 2021.

4.



Privacy Policy
Copyright © 2020 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.